Skip to main content
. 2021 Apr 2;13(4):484. doi: 10.3390/pharmaceutics13040484

Figure 2.

Figure 2

Curcumin’s potential and molecular targets in inflammatory bowel disease (IBD) treatment, adapted from [25,66,67,68,69,70,71,72,73,74].